openPR Logo
Press release

Strategic Advancements in Drug Development are Beholding the Growth of Proteasome Inhibitors Pipeline | Top Key Players are Celgene, Takeda, Amgen, Conatus Pharmaceuticals Inc.

06-14-2019 11:51 AM CET | Health & Medicine

Press release from: Pharma Proff

Proteasomes are small, barrel-formed structures found in cells having a function of degrading the misfolded and non-useful proteins inside the cells. Proteasome inhibitors focus on proteasomes in the disease cells and hinder their action by binding to them. Once, proteasome action is lost, the proteins begin to assemble inside the malignant cells and later burst due to overaccumulation, causing cell death. The proteasome inhibitors are being considered for the treatment of various diseases, including myeloma and immune system related disorders.

Download the sample report at: https://www.pharmaproff.com/request-sample/1240

Velcade and Ninlaro of Takeda Pharmaceutical Company Limited are the approved proteasome inhibitors by the U.S. Food and Drug Administration (USFDA) for the treatment of multiple myeloma. Also, Velcade is approved inhibitor for the treatment of mantle cell lymphoma.
According to the research findings, majority of the pipeline drug candidates are being developed to be administered by intravenous route. It has been observed that the intravenous route of medication is convenient and provides improved patient’s compliance. Administration of proteasome inhibitors through intravenous route has also shown promising results in clinical studies.

Get the detailed analysis at: https://www.pharmaproff.com/report/proteasome-inhibitors-therapeutics

Companies that are involved in developing proteasome inhibitors have shown positive clinical results in the various phases of drug development. For instance, in May 2016, Conatus Pharmaceuticals Inc. announced positive topline data of phase II trial of Emricasan for the treatment of liver cirrhosis. The data demonstrated that Emricasan had a favorable safety profile and was well-tolerated.

It has been observed that many pharmaceutical companies are entering into merger & acquisitions for the development of proteasome inhibitors and their geographical expansion. For instance, in April 2008, Takeda Pharmaceutical Company Limited Acquired Millennium Pharmaceuticals Inc. for $8.8 billion. Later in November 2009, Millennium Pharmaceuticals Inc., which became the wholly-owned subsidiary of Takeda Pharmaceutical Company Limited initiated a Phase I clinical trial of MLN9708, a second-generation proteasome inhibitor.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1240

Takeda Pharmaceutical Company Limited, Amgen Inc., Conatus Pharmaceuticals Inc., Hibiskus Biopharma Inc., and Celgene Corporation are some of the companies involved in the development of proteasome inhibitors.
The report comprises detailed pipeline analysis of proteasome inhibitors under development. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the development of proteasome inhibitors. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to proteasome inhibitors.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Strategic Advancements in Drug Development are Beholding the Growth of Proteasome Inhibitors Pipeline | Top Key Players are Celgene, Takeda, Amgen, Conatus Pharmaceuticals Inc. here

News-ID: 1775717 • Views:

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developments
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant Growth due to Increasing Strategic Developments in the Coming Years | Top Players are Orphazyme A/S, IntraBio Ltd., CTD Holdings, Inc., Mallinckrodt Pharmaceuticals, SOM Biotec
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for Pharmaceutical

Mevastatin Market Is Booming Worldwide |Zhejiang Hisun Pharmaceutical, Guangdong …
Global Mevastatin Market Size research report 2022 offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market. This study provides information about the sales and revenue during the historic and forecasted period of (2022 to 2028). Understanding the segments helps in identifying the importance of different factors that aid market growth. Estimations about the CAGR value for
Global Specialty Pharmaceutical Market Driving Future Growth on Specialty Pharma …
Global Specialty Pharmaceutical Industry Synopsis: The Specialty Pharmaceutical Market report provides a detailed analysis of this business space. The market is analyzed in terms of production as well as consumption. Based on the production aspect, the report includes particulars pertaining to the manufacturing processes of the product, alongside revenue and gross margins of the respective manufacturers. The Global Specialty Pharmaceutical Market will reach xxx Million USD in 2020 with CAGR xx%
Metronidazole Market by Top Manufacturers – Hongyuan Pharmaceutical, Yinhe Aar …
Metronidazole is an antibiotic and antiprotozoal medication, with the chemical formula C6H9N3O3 of can be used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis among others. Metronidazole is white crystalline powder, which can also be called as Fragyl Orvagil, Trichazol, Metronid, etc. Get Sample Copy of this Report @ https://www.bigmarketresearch.com/request-sample/2724380?utm_source=Anil&utm_medium=OPR Scope of the Report: This report focuses on the Metronidazole in global market, especially in
Metronidazole Market by Top Manufacturers – Hongyuan Pharmaceutical, Yinhe Aar …
Metronidazole is an antibiotic and antiprotozoal medication, with the chemical formula C6H9N3O3 of can be used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis among others. Metronidazole is white crystalline powder, which can also be called as Fragyl Orvagil, Trichazol, Metronid, etc. Get Sample Copy of this Report @ https://www.bigmarketresearch.com/request-sample/2724380?utm_source=Anil&utm_medium=OPR Scope of the Report: This report focuses on the Metronidazole in global market, especially in
Metronidazole Market to 2023 (+5% CAGR Expected) Top Player Profiles – Hongyua …
Metronidazole is an antibiotic and antiprotozoal medication, with the chemical formula C6H9N3O3 of can be used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis among others. Metronidazole is white crystalline powder, which can also be called as Fragyl Orvagil, Trichazol, Metronid, etc. Get Sample Copy of this Report @ https://www.bigmarketresearch.com/request-sample/2724380?utm_source=Anil&utm_medium=OPR Scope of the Report: This report focuses on the Metronidazole in global market, especially in
Metronidazole Market by Top Key Participant Hongyuan Pharmaceutical, Yinhe Aarti …
Metronidazole is an antibiotic and antiprotozoal medication, with the chemical formula C6H9N3O3 of can be used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis among others. Metronidazole is white crystalline powder, which can also be called as Fragyl Orvagil, Trichazol, Metronid, etc. Get Sample Copy of this Report @ https://www.researchbeam.com/global-metronidazole-2018-by-manufacturers-regions-type-and-application-forecast-to-2023-market/request-sample?utm_source=Anil Scope of the Report: This report focuses on the Metronidazole in global market, especially in North